Edouard Girard1,2, Olivier Risse3, Julio Abba3, Maud Medici4,5, Vincent Leroy6, Mircea Chirica3, Christian Letoublon3. 1. Service de Chirurgie Digestive et Générale, Hôpital Michallon, Centre Hospitalier Universitaire Grenoble-Alpes, Boulevard de la Chantourne, 38700, La Tronche, France. egirard1@chu-grenoble.fr. 2. Laboratory TIMC, CNRS, Grenoble-Alpes University, Grenoble, France. egirard1@chu-grenoble.fr. 3. Service de Chirurgie Digestive et Générale, Hôpital Michallon, Centre Hospitalier Universitaire Grenoble-Alpes, Boulevard de la Chantourne, 38700, La Tronche, France. 4. Laboratory TIMC, CNRS, Grenoble-Alpes University, Grenoble, France. 5. Clinical Investigation Center for Innovative Technologies, Grenoble-Alpes University, Grenoble, France. 6. Department of Gastroenterology, Grenoble-Alpes University, Grenoble, France.
Abstract
PURPOSE: Internal biliary stenting (IBS) was reported to decrease biliary complications after liver transplantation (LT) but data in literature is scarce. The aim of the present study was to evaluate our experience with end-to-end choledoco-choledocostomy during liver transplantation with special focus on the influence of IBS on patient and biliary outcomes. METHODS: Between 2009 and 2013, 175 patients underwent deceased donor LT with end-to-end choledoco-choledocostomy and were included in the study. Supra-papillary silastic stent was inserted in 67 patients (38%) with small-size (< 5 mm) bile ducts (recipient or donor). Endoscopic retrograde cholangiopancreatography (ERCP) was scheduled for IBS removal, 6 months after LT. Operative outcomes and survival of patients who received internal stenting (IBS group) were compared with those of patients who did not (no-IBS group). Risk factors for biliary anastomotic complications were identified. RESULTS: Ten patients died (6%) and 104 (59%) experienced postoperative complications. Five-year patient and graft survival rates were 77 and 74%, respectively. Biliary complications were recorded in 61 patients (35%) and were significantly decreased by IBS insertion (p = 0.0003). Anastomotic fistulas occurred in 23 patients (13%) and stenoses in 44 patients (25%). On multivariate analysis, high preoperative MELD scores (p = 0.02) and hepatic artery thrombosis (p < 0.0001) were predictors of fistula; absence of IBS was associated with both fistula (p = 0.014) and stricture (p = 0.003) formation. CONCLUSIONS: IBS insertion during LT decreases anastomotic complication.
PURPOSE: Internal biliary stenting (IBS) was reported to decrease biliary complications after liver transplantation (LT) but data in literature is scarce. The aim of the present study was to evaluate our experience with end-to-end choledoco-choledocostomy during liver transplantation with special focus on the influence of IBS on patient and biliary outcomes. METHODS: Between 2009 and 2013, 175 patients underwent deceased donor LT with end-to-end choledoco-choledocostomy and were included in the study. Supra-papillary silastic stent was inserted in 67 patients (38%) with small-size (< 5 mm) bile ducts (recipient or donor). Endoscopic retrograde cholangiopancreatography (ERCP) was scheduled for IBS removal, 6 months after LT. Operative outcomes and survival of patients who received internal stenting (IBS group) were compared with those of patients who did not (no-IBS group). Risk factors for biliary anastomotic complications were identified. RESULTS: Ten patients died (6%) and 104 (59%) experienced postoperative complications. Five-year patient and graft survival rates were 77 and 74%, respectively. Biliary complications were recorded in 61 patients (35%) and were significantly decreased by IBS insertion (p = 0.0003). Anastomotic fistulas occurred in 23 patients (13%) and stenoses in 44 patients (25%). On multivariate analysis, high preoperative MELD scores (p = 0.02) and hepatic artery thrombosis (p < 0.0001) were predictors of fistula; absence of IBS was associated with both fistula (p = 0.014) and stricture (p = 0.003) formation. CONCLUSIONS:IBS insertion during LT decreases anastomotic complication.
Authors: S Saab; P Martin; G Y Soliman; G A Machicado; B E Roth; G Kunder; S H Han; D G Farmer; R M Ghobrial; R W Busuttil; R A Bedford Journal: Liver Transpl Date: 2000-09 Impact factor: 5.799
Authors: Georgios C Sotiropoulos; George Sgourakis; Arnold Radtke; Ernesto P Molmenti; Konstantinos Goumas; Sofia Mylona; Ioannis Fouzas; Constantine Karaliotas; Hauke Lang Journal: Transplantation Date: 2009-06-15 Impact factor: 4.939
Authors: A Amador; R Charco; J Martí; M Navasa; A Rimola; D Calatayud; G Rodriguez-Laiz; J Ferrer; J Romero; C Ginesta; C Fondevila; J Fuster; J C García-Valdecasas Journal: Clin Transplant Date: 2007 Jul-Aug Impact factor: 2.863
Authors: Sascha Weiss; Sven-Ch Schmidt; Frank Ulrich; Andreas Pascher; Guido Schumacher; Martin Stockmann; Gero Puhl; Olaf Guckelberger; Ulf P Neumann; Johann Pratschke; Peter Neuhaus Journal: Ann Surg Date: 2009-11 Impact factor: 12.969